Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.71 |
| ▸ | GPR4 | P46093 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-158809 SCHEMBL7944169 | 0.99 | AGTR2 (0.70) | AGTR2AGTR1GPR4 | |
| SCHEMBL8972219 | 0.93 | AGTR1 (0.72) | AGTR2AGTR1 | |
| SCHEMBL8971497 | 0.92 | AGTR2 (0.60) | AGTR2AGTR1GPR4 | |
| SCHEMBL9406686 | 0.91 | AGTR1 (0.73) | AGTR2AGTR1 | |
| SCHEMBL8741166 | 0.91 | AGTR2 (0.61) | AGTR2AGTR1GPR4 | |
| SCHEMBL2774605 | 0.90 | AGTR2 (0.58) | AGTR2AGTR1 | |
| SCHEMBL9657133 | 0.89 | AGTR2 (0.59) | AGTR2AGTR1GPR4 | |
| SCHEMBL9655735 | 0.89 | AGTR2 (0.57) | AGTR2AGTR1 | |
| SCHEMBL7388992 | 0.89 | AGTR2 (0.59) | AGTR2AGTR1GPR4 | |
| SCHEMBL9701759 | 0.88 | AGTR2 (0.59) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561977-B1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 2004-05-26 | — | — | EP | claimed |
| US-20030198676-A1 | Sustained-release preparation for AII antagonist, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-23 | — | — | US | claimed |
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | claimed |
| US-6589547-B1 | Sustained-release preparation for AII antagonist, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-08 | — | — | US | claimed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | claimed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | claimed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | claimed |
| US-20030049643-A1 | Constitutively desensitized G protein-coupled receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-03-13 | — | — | US | claimed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | claimed |
| US-6531482-B1 | Administering matrix accumulation inhibiting amount of angiotensin II type 1 vascular receptor antagonist | VANDERBILT UNIVERSITY | 2003-03-11 | — | — | US | claimed |
| EP-0480659-B1 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0720477-A1 | METHOD AND COMPOSITIONS FOR MAINTAINING GLOMERULAR FILTRATION RATE WHILE INHIBITION EXTRACELLULAR MATRIX ACCUMULATION | VANDERBILT UNIVERSITY (US) | 1996-07-10 | — | — | EP | claimed |
| EP-0720477-A4 | METHOD AND COMPOSITIONS FOR MAINTAINING GLOMERULAR FILTRATION RATE WHILE INHIBITION EXTRACELLULAR MATRIX ACCUMULATION | UNIV VANDERBILT (US) | 1996-03-04 | — | — | EP | claimed |
| US-5334718-A | Decyclizing a phenyl or a pyridyl or pyrimidyl group by reacting with a base to get angiotension antagonist | ZENECA LIMITED (GB) | 1994-08-02 | — | — | US | claimed |
| WO-1994005289-A1 | METHOD AND COMPOSITIONS FOR MAINTAINING GLOMERULAR FILTRATION RATE WHILE INHIBITION EXTRACELLULAR MATRIX ACCUMULATION | VANDERBILT UNIVERSITY (US) | 1994-03-17 | — | — | WO | claimed |
| US-5260322-A | Angiotension II antagonists in the treatment of hyperuricemia | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | claimed |
| EP-0554098-A2 | Process for the preparation of imidazo 4,5-b pyridine derivatives | ZENECA LIMITED (GB) | 1993-08-04 | — | — | EP | claimed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| EP-0480659-A2 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885GPR4 318/4885 |
| US-20030198676-A1 | Sustained-release preparation for AII antagonist, production and use thereof | AGTR2, AGTR1, PER2 | AGTR2 1/4885AGTR1 2/4885GPR4 1101/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885GPR4 318/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885GPR4 491/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885GPR4 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.